



1/39

FIGURE 1A




2/39

FIGURE 1B



3/39

FIGURE 1C




SUBSTITUTE SHEET (RULE 26)


4/39

FIGURE 2A

Size: 0.6360 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

6/39 236.56°C

FIGURE 2C


Size: 1.4230 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN



SUBSTITUTE SHEET (RULE 26)


Size: 1.0400 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN

FIGURE 2D



8/39


FIGURE 3A



SUBSTITUTE SHEET (RULE 26)

9/39


FIGURE 3B




SUBSTITUTE SHEET (RULE 26)

10/39

FIGURE 3C




11/39



SUBSTITUTE SHEET (RULE 26)

12/39

FIGURE 4



13/39

FIGURE 5





FIGURE 6A

Size: 3.3010 mg
Method: 10 deg ramp to 300 deg


methylethyl ketone solvent



SUBSTITUTE SHEET (RULE 26)

15/39


FIGURE 7



SUBSTITUTE SHEET (RULE 26)


16/39

FIGURE 8




SUBSTITUTE SHEET (RULE 26)

17/39




SUBSTITUTE SHEET (RULE 26)

18/39




SUBSTITUTE SHEET (RULE 26)

19/39




SUBSTITUTE SHEET (RULE 26)


200004163



21/39




SUBSTITUTE SHEET (RULE 26)




23/39

FIGURE 15




24/39

FIGURE 16




25/39

FIGURE 17



26/39

FIGURE 18




SUBSTITUTE SHEET (RULE 26)

27/39

FIGURE 19


Form

A: Cooling Rate
B: Purity
C: End Point



28/39

FIGURE 20




29/39

INEL


2 Theta

FIGURE 21



SUBSTITUTE SHEET (RULE 26)

FIGURE 22




SUBSTITUTE SHEET (RULE 26)

31/39

FIGURE 23

Eplerenone: Dose-Ranging Heart Failure Study



Year	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

FIGURE 24

Baseline Characteristics									
Variable Mean (SD)	Placebo n=55	EPLERENONE						p-value	
		EPL 25 QD n=63	EPL 25 QD n=52	BID	EPL 50 QD n=55	EPL 100 QD n=50	SPIRO 25 QD n=46		
Age	60	62	61	62	61	62	62	0.9	
M/I (%)	80/20	76/24	81/19	80/20	78/22	72/28		0.9	
NYI IA II III (%)	100	97	94	100	98	100		32/39	
NYI IA IV (%)	0	3	6	0	2	0			
II (%)	29	29	29	30	30	30			
IIR (BPM)	74	76	76	73	76	76		0.8	
SBP (mm Hg)	127	124	128	125	129	130		0.4	
DBP (mm Hg)	78	78	79	78	78	78		1.0	
K ⁺ (mmol/L)	4.48	4.38	4.28	4.34	4.38	4.45		0.2	
Creatinine (pmol/L)	107	109	104	107	109	107		0.7	

33/39

FIGURE 25

Concurrent Medications


Category	% Patients	Avg. Dose (mg/day)
• ACE Inhibitor		
Captopril	30	62
Enalapril	30	15
Lisinopril	15	15
• Loop Diuretic		
Furosemide	85	50
• Other		
Digitalis	55	
beta-Blockers	35	
Aspirin	35	
Anticoagulants	35	
Potassium Supplements	25	
Calcium Antagonist	25	

34/39

FIGURE 26

DBP
P vs. E 50 mg/day vs. S
Mean Change (\pm SEM) at Week 12

> 90 mmHg at Baseline




35/39

FIGURE 27


Aldosterone Excretion Rate

Mean Change (+/- SEM) from Baseline at Week 12



36/39

FIGURE 28




SUBSTITUTE SHEET (RULE 26)

FIGURE 29

BNP


Mean Change (+/- SEM) from Baseline at Week 12



Placebo	E 25 QD	E 25 BID	E 50 QD	E 100 QD	SPIRO
0.028	0.056	0.125	0.036	0.059	
p-value (vs. Placebo)					

FIGURE 30

BNP
Mean Change (\pm SEM) from Baseline at Week 12
> 14.2 pmol/L at Baseline



Placebo	E 25 QD	E 25 BID	E 50 QD	E 100 QD	SPIRO
0.040	0.102	0.051	0.054	0.064	
p-value (vs. Placebo)					

39/39

FIGURE 31

Study Schematic For Biological Evaluation II: Multicenter, Randomized
Double-Blind, Parallel Group Trial
Minimum Trial Duration 1.012 Deaths

